Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5313875 | 0.91 | MEN1 (0.54) | LTA4HMEN1KMT2AHRH3ALDH1A1 | |
| SCHEMBL5657184 | 0.89 | LTA4H (0.57) | LTA4HHRH3SCN5ASCN9AFAAH | |
| SCHEMBL5310186 | 0.89 | LTA4H (0.69) | LTA4HMEN1KMT2AALDH1A1FAAH | |
| SCHEMBL3043169 | 0.82 | LTA4H (0.77) | LTA4HHRH3FAAH | |
| SCHEMBL5317798 | 0.82 | LTA4H (0.77) | LTA4HMEN1KMT2AHRH3ALDH1A1 | |
| SCHEMBL5312528 | 0.81 | CYP2D6 (0.47) | LTA4HHRH3ALDH1A1SCN5ASCN9A | |
| SCHEMBL5663496 | 0.80 | LTA4H (0.60) | LTA4HHRH3FAAHMCHR2MCHR1 | |
| SCHEMBL5313809 | 0.80 | LTA4H (0.67) | LTA4HKMT2AFAAHDRD2MCHR2 | |
| SCHEMBL5661085 | 0.79 | LTA4H (0.59) | LTA4HHRH3FAAHMCHR2MCHR1 | |
| SCHEMBL5661080 | 0.79 | LTA4H (0.59) | LTA4HHRH3FAAHMCHR2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885MEN1 4385/4885KMT2A 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.